Fig. 4.

In vivo evaluation in SCID mice bearing LAPC-9 tumors that were injected with ¹²⁴I-labeled minibodies (A2, A11, and C5). a Coregistered microPET/microCT scan of SCID mice bearing LAPC-9 (PSCA-positive human prostate cancer) xenografts. The mice were injected with radiolabeled minibody variants (A2, A11, and C5) and scanned at 21 h post-injection. Coronal projections are presented that are adjusted to the same scale. b Biodistribution, Tu/Bl (tumor/blood) and imaging data Tu/Ba (tumor/background) at 21 h post-injection. Tumor and normal organ uptakes are expressed as percent injected dose per gram (%ID/g ± SE)